Drug-eluting stents

Coronary disease

Retrospective Analysis of DCB vs DES in Side-Branch Treatment

Coronary bifurcations are one of the most challenging scenarios in percutaneous coronary intervention (PCI) due to their...

Dr. Omar Tupayachi - 4 November, 2025

Chronic Ischemic cardiopathy

TCT 2025 | TUXEDO-2: Ultra-Thin Struts Versus Xience in Diabetic Patients with Multivessel Disease

It is well known that diabetic patients undergoing PCI often present with more extensive coronary artery disease,...

Dr. Andrés Rodríguez - 29 October, 2025

Coronary Disease

TCT 2025 | INFINITY–SWEDEHEART: Long-Term Outcomes of the Bioadaptive Coronary Implant Versus Drug-Eluting Stent

The bioadaptive coronary implant DynamX (Elixir Medical, California) was developed to restore normal vascular function after angioplasty,...

Dr. Juan Manuel Pérez - 29 October, 2025

Coronary disease

TCT 2025 | REC-CAGEFREE I: Three-Year Follow-Up of Drug-Coated Balloon Angioplasty vs Stent in De Novo Coronary Lesions

The REC-CAGEFREE I trial evaluated the safety and efficacy of paclitaxel-coated balloon (DCB) angioplasty versus sirolimus-eluting stent...

Dr. Juan Manuel Pérez - 29 October, 2025

Coronary disease

TCT 2025 | IRONMAN II Study: Sirolimus-Eluting Iron Bioresorbable Stent in Coronary Artery Disease

Bioresorbable coronary stents represent a step toward strategies without permanent metallic implants, although the first polymer-based platforms...

Dr. Juan Manuel Pérez - 29 October, 2025

Acute coronary syndromes

TCT 2025 | SELUTION4ISR: sirolimus-eluting balloon for in-stent restenosis

In-stent restenosis (ISR) continues to be a relevant clinical challenge in contemporary PCI practice. In the DES...

Dr. Omar Tupayachi - 28 October, 2025

Acute coronary syndromes

TCT 2025 | SELUTION DeNovo: sirolimus-eluting balloon vs. stent in de novo coronary lesions

The use of drug-eluting stents (DES) remains the standard strategy in most percutaneous coronary intervention (PCI) procedures....

Dr. Omar Tupayachi - 28 October, 2025

Coronary disease

Use of DCB in Coronary Territory: Position Document of the Academic Research Consortium

The use of drug-coated balloons (DCB) is emerging as one of the most promising strategies in coronary...

Dr. Omar Tupayachi - 7 October, 2025

Drug-eluting stents

Retrospective Analysis of DCB vs DES in Side-Branch Treatment

TCT 2025 | TUXEDO-2: Ultra-Thin Struts Versus Xience in Diabetic Patients with Multivessel Disease

TCT 2025 | INFINITY–SWEDEHEART: Long-Term Outcomes of the Bioadaptive Coronary Implant Versus Drug-Eluting Stent

TCT 2025 | REC-CAGEFREE I: Three-Year Follow-Up of Drug-Coated Balloon Angioplasty vs Stent in De Novo Coronary Lesions

TCT 2025 | IRONMAN II Study: Sirolimus-Eluting Iron Bioresorbable Stent in Coronary Artery Disease

TCT 2025 | SELUTION4ISR: sirolimus-eluting balloon for in-stent restenosis

TCT 2025 | SELUTION DeNovo: sirolimus-eluting balloon vs. stent in de novo coronary lesions

Use of DCB in Coronary Territory: Position Document of the Academic Research Consortium

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Accesos